Two governance commitments, both unkept, drove Umesh Patel to resign from the Northann Corp. (NCL) board effective April 14, 2026. In a letter addressed to Lin Li (Ken) and members of the board, Patel named unpaid board compensation and the company's failure to secure or maintain Directors and Officers liability insurance as the specific grounds. The resignation arrived as Exhibit 99.1 in the same 8-K Northann Corp. filed as a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard.
What Patel's letter states
Patel described both the compensation shortfall and the D&O gap as commitments the company made at the time of his appointment and did not honor. He characterized them as "fundamental to the governance framework and risk management expectations associated with board service." Prior discussions produced no resolution on either point. Their absence, he wrote, left him no alternative but to step down.
He also recommended that Northann Corp. address these governance gaps promptly to ensure compliance with standard board practices. The letter, signed by Patel, carries an effective date of April 14, 2026.
The delisting dimension
The 8-K form type, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard, signals that Northann Corp.'s listing exchange has formally flagged a rule breach. The disclosed exhibit does not name the exchange, identify which continued listing standard the company failed to meet, or quantify any financial shortfall that triggered the notice.
D&O liability insurance is a baseline governance requirement for public company board service. Directors carry personal exposure to shareholder litigation, and the coverage is the mechanism Northann Corp. had committed to maintain. Its absence gave Patel concrete legal grounds for concern, separate from the compensation dispute. Both issues surface in a single 8-K filing.
What the filing leaves open
The disclosed exhibit contains no response from Northann Corp. to Patel's stated reasons. The dollar amount of overdue board compensation, the duration of the D&O coverage lapse, and any cure deadline the exchange may have set for the listing deficiency are all absent from the filing.